Insiders Trades
STRATA Skin Sciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 17 Jul 2024.
STRATA Skin Sciences, Inc.: what insiders have been doing
Every trade that managers of STRATA Skin Sciences, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Irvington, United States. It was founded in 1989. From 18 October 2025 to 18 October 2026, the disclosure feed for STRATA Skin Sciences, Inc. logged 1 filing by 1 insider.
There is no open-market purchase to report; the filings show 1 sale worth €6,250 by 1 insider. At €6,250, the sale published on 18 November 2025 by Rubinstein Samuel is the largest of the period.
Compared with its exchange (5,816 companies, median 19 filings), a count of 1 filing is below the norm. Over the whole record (from 2021), the tally stands at 13 purchases and 2 sales.
Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
28
Thresholds
n/a
Buy Volume
€211,322
13 ops. · all time
Sell Volume
€6,545
2 ops. · all time
Who traded when
BuySaleSamuel Rubinstein1 sale
Since the insiders bought
- +498.0%Entry US$0.50 · Close at T+365 US$2.99
- +429.0%Entry US$0.56 · Close at T+365 US$2.97
- +429.0%Entry US$0.56 · Close at T+365 US$2.97
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$30.7M
Gross profitUS$17.9M58% margin
EBITDAUS$177k1% margin
Net income-US$6.3M-20.4% margin
Valuation
P/Book0.0x
Beta0.03
Balance sheet & cash
Market capUS$588
Total debtUS$16.3M
Free Cash Flow-US$4.3M
Debt / Equity559%
Profitability & ownership
ROE-158.9%
ROA-11.1%
% insiders10.0%
% institutions25.4%
Last declaration on 18 November 2025
Declarations28 total
5,500 shares@ US$1.328.5% of flowCommon StockSEC:0001051514-25-000016:0
230,573 shares@ €2.8803100.0% of flowCommon StockSEC:0001213900-24-062197:0
Canonical exit: 13 Oct 2024 (T+90)
230,573 shares@ €2.8803100.0% of flowCommon StockSEC:0001213900-24-062198:0
Canonical exit: 13 Oct 2024 (T+90)
19,100 shares@ US$3.14100.0% of flowCommon StockSEC:0001051514-24-000005:0
Canonical exit: 13 Oct 2024 (T+90)
14,338 shares@ US$0.44100.0% of flowSSKN Common StockSEC:0001051514-23-000070:0
Canonical exit: 29 Feb 2024 (T+90)
1,000 shares@ US$0.320.4% of flowCommon StockSEC:0001051514-23-000064:0
42,000 shares@ US$0.67435.1% of flowSSKN Common StockSEC:0001051514-23-000036:0
Canonical exit: 8 Nov 2023 (T+90)
5,151 shares@ US$0.6811.3% of flowSSKN Common StockSEC:0001051514-23-000038:0
Canonical exit: 8 Nov 2023 (T+90)
33,981 shares@ US$1.0344.0% of flowSSKN Common StockSEC:0001051514-23-000028:0
36,408 shares@ US$1.0341.9% of flowSSKN Common StockSEC:0001051514-23-000029:0
38,835 shares@ US$1.0349.1% of flowSSKN Common StockSEC:0001051514-23-000030:0
33,981 shares@ US$1.0379.4% of flowSSKN Common StockSEC:0001051514-23-000032:0
36,408 shares@ US$1.0379.4% of flowSSKN Common StockSEC:0001051514-23-000031:0
37,838 shares@ US$0.92545.6% of flowSSKN Common StockSEC:0001051514-22-000075:0
9,106 shares@ US$0.96120.6% of flowSSKN Common StockSEC:0001051514-22-000074:0
43,244 shares@ US$0.92550.9% of flowSSKN Common StockSEC:0001051514-22-000076:0
9,756 shares@ US$0.96120.6% of flowSSKN Common StockSEC:0001051514-22-000073:0
1,050 shares@ US$1.041.4% of flowSSKN Common StockSEC:0001051514-22-000065:0
Canonical exit: 13 Sept 2022 (T+90)
23,131 shares@ US$1.1288.7% of flowSSKN Common StockSEC:0001051514-22-000057:0
Canonical exit: 10 Aug 2022 (T+90)
16,950 shares@ US$1.733632.4% of flowSSKN Common StockSEC:0001051514-22-000035:0
Canonical exit: 23 Jun 2022 (T+90)
33,300 shares@ US$1.573564.9% of flowSSKN Common StockSEC:0001051514-22-000032:0
Canonical exit: 22 Jun 2022 (T+90)
14,783 shares@ US$1.58225.8% of flowSSKN Common StockSEC:0001051514-22-000033:0
Canonical exit: 22 Jun 2022 (T+90)
1,155 shares@ €1.18211.8% of flowSSKN Common StockSEC:0001051514-21-000064:0
Canonical exit: 6 Dec 2021 (T+90)
20,000 shares0SSKN Common StockSEC:0001051514-21-000034:0
25 of 28 declarations
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences, Inc. is a U.S. medical technology company focused on dermatology and listed on the NASDAQ market in the United States. Headquartered in Horsham, Pennsylvania, the company serves dermatologists and their patients with targeted treatment platforms for chronic skin conditions. Its profile is that of a niche med-tech player rather than a broad pharmaceutical company, with a business model that combines equipment sales and recurring revenue from utilization of its installed base.
The company has evolved around excimer laser technology and later sharpened its focus through portfolio reshaping and acquisitions. STRATA moved away from its former MelaFind initiative and changed its name in 2016. Today, its core commercial offerings include the XTRAC® and Pharos® excimer lasers and the VTRAC® lamp system, which are used in the treatment of psoriasis, vitiligo, and other inflammatory or autoimmune dermatologic disorders. In 2022, STRATA broadened its strategy with the acquisition of the TheraClear® Acne Therapy System, marketed as TheraClear® X, giving the company exposure to the acne treatment market as well.
Read moreShow less
From a competitive standpoint, STRATA differentiates itself through highly targeted UVB-light treatment technologies aimed at large but often under-served dermatology indications. The company reports an installed base of systems in dermatology offices, primarily in the United States, alongside a smaller but growing international footprint. Its economics are driven by recurring procedure revenue, which can provide more stability than an equipment-only model.
Recent developments suggest a company still in an operational rebuilding and expansion phase. In 2025, STRATA reported modest quarterly revenue growth, continued international momentum, and progress on expanding CPT reimbursement codes for inflammatory and autoimmune skin diseases in the United States, potentially increasing the addressable market. The company also obtained Mexican regulatory clearance for TheraClearX and began first commercial placements there. At the same time, recent SEC filings show that the common stock was delisted from the Nasdaq Capital Market as of February 19, 2026 and is now quoted over the counter (OTC), which is a material consideration for investors assessing liquidity and financing risk.
For French, Belgian, and Swiss investors, STRATA is therefore a U.S. healthcare small cap with exposure to both clinical adoption and reimbursement expansion. The equity should be viewed as a higher-risk, higher-volatility med-tech name, with progress dependent on commercialization execution, payer coverage expansion, and balance-sheet support.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
